ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

taletrectinib

Also written as “Taletrectinib”, “AB-106” and “DS6051b”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Neoplasms, led by 2 companies.

Drug pageTaletrectinib: every studyAll 11 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Aug 12, 202411 company-led studies, 5 open or runningNext primary completion: Feb 2, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Nuvation Bio105 open or runningphase 3since Aug 12, 2024Oct 15, 2014Feb 2, 2027phase 1 · NCT07742384
Daiichi Sankyoits history only10 open or runningphase 1since Feb 2, 2016Feb 2, 2016none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Nuvation Bio only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Oct 15, 2014First study: phase 1 study in NeoplasmsFirst studyNCT02279433 · 46 enrolled · United States
  2. May 12, 2020Phase 2 study in Carcinoma, Non-Small-Cell LungNCT04395677 · 173 enrolled · China
  3. Jun 9, 2020Named taletrectinibINNProposed as its International Nonproprietary Name in WHO's List 123 · before, AB-106
  4. Oct 30, 2020Phase 2 study in Solid TumorNCT04617054 · 14 enrolled · China
  5. May 27, 2021Phase 2 study in Carcinoma, Non-Small-Cell LungNCT04919811 · 217 enrolled · United States, Canada, China and more
  6. Jul 9, 20212 phase 1 studies in Solid TumorNCT05357911, NCT05357820
  7. Oct 26, 2022Phase 1 study in Pharmacokinetic StudyNCT05609929 · 24 enrolled · China
  8. Aug 12, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06564324 · 194 planned · China
  9. Aug 18, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungNCT07154706 · 180 planned · United States, Canada, China
  10. Jul 13, 2026Phase 1 study in Healthy Adult ParticipantsNCT07742384 · 56 planned

Ahead

  1. Feb 2, 2027Primary completion: phase 1 study in Healthy Adult ParticipantsNCT07742384
  2. Jan 2029Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT06564324
  3. Aug 30, 2030Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT07154706

TargetBeta

“An orally available inhibitor of the receptor tyrosine kinases C-ros oncogene 1 (ROS1) and the neurotrophic tyrosine receptor kinase (NTRK) types 1, 2 and 3, ”NCIt, by rule
“Proto-oncogene tyrosine-protein kinase ROS inhibitor; Neurotrophic tyrosine kinase receptor inhibitor”ChEMBL 37, by rule

Other programs on the same 4 targets

ProgramCompanyFurthest phaseStudies
repotrectinibruleBristol-Myers Squibbphase 39

Studies

All 10 Nuvation Bio leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07742384Healthy Adult Participants1Not yet recruitingFeb 2, 202756
NCT07154706Carcinoma, Non-Small-Cell Lung · United States, Canada, China3RecruitingAug 30, 2030180
NCT06564324Carcinoma, Non-Small-Cell Lung · China3RecruitingJan 2029194
NCT05609929Pharmacokinetic Study · China1CompletedJan 20, 202324
NCT05357911Solid Tumor · China1CompletedAug 20, 202116
NCT05357820Solid Tumor · China1CompletedDec 3, 202156
NCT04919811Carcinoma, Non-Small-Cell Lung · United States, Canada, China and more2Active, not recruitingJun 11, 2025217
NCT04617054Solid Tumor · China2TerminatedDec 6, 202414
NCT04395677Carcinoma, Non-Small-Cell Lung · China2Active, not recruitingJun 7, 2024173
NCT02279433Neoplasms · United States1CompletedMar 201946

How it is read

Names in the registry

  • “Taletrectinib”, 5 entries
  • “AB-106”, 2 entries
  • “DS6051b”, 1 entry
  • “DS-6051b”, 1 entry
  • “AB-106, Itraconazole”, 1 entry

Codes read as this program: AB106.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.